


Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO				<div style="text-align: center;">  </div>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	09/585,821
				Filing Date	June 1, 2000
				First Named Inventor	Wilkison <i>et al.</i>
				Group Art Unit	1645
Attorney Docket Number	08140.ARTDIV				
Sheet	1	of	4		

RECEIVED
 AUG 10 2001
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clmns, Lns, Where Relevant Passages/Relevant Figs Appear
		Number	Kind Code (if known)			
<i>B</i>	AA	5,041,138		Vacanti <i>et al.</i>	08/20/1991	
<i>B</i>	AB	5,144,016		Skjak-Braek <i>et al.</i>	09/01/1992	
<i>B</i>	AC	5,486,359		Caplan <i>et al.</i>	01/23/1996	
<i>B</i>	AD	5,516,532		Atala <i>et al.</i>	05/14/1996	
<i>B</i>	AE	5,536,656		Kemp <i>et al.</i>	07/16/1996	
<i>B</i>	AF	5,709,854		Griffith-Cima <i>et al.</i>	01/20/1998	
<i>B</i>	AG	5,723,331		Tubo <i>et al.</i>	03/03/1998	
<i>B</i>	AH	5,736,372		Vacanti <i>et al.</i>	04/07/1998	
<i>B</i>	AI	5,736,396		Bruder <i>et al.</i>	08/24/1999	
<i>B</i>	AJ	5,741,685		Vacanti	04/21/1998	
<i>B</i>	AK	5,759,830		Vacanti <i>et al.</i>	06/02/1998	
<i>B</i>	AL	5,770,193		Vacanti <i>et al.</i>	06/23/1998	
<i>B</i>	AM	5,770,417		Vacanti <i>et al.</i>	06/23/1998	
<i>B</i>	AN	5,786,207		Katz <i>et al.</i>	07/28/1998	
<i>B</i>	AO	5,804,178		Vacanti <i>et al.</i>	09/08/1998	
<i>B</i>	AP	5,811,094		Caplan <i>et al.</i>	09/22/1998	
<i>B</i>	AQ	5,827,735		Young <i>et al.</i>	10/27/1998	
<i>B</i>	AR	5,855,610		Vacanti <i>et al.</i>	01/05/1999	
<i>B</i>	AS	5,863,531		Naughton <i>et al.</i>	01/26/1999	
<i>B</i>	AT	5,879,940		Torok-Storb <i>et al.</i>	03/09/1999	
<i>B</i>	AU	5,902,741		Purchio <i>et al.</i>	05/11/1999	
<i>B</i>	AV	5,908,784		Johnstone <i>et al.</i>	06/01/1999	
<i>B</i>	AW	5,942,225		Bruder <i>et al.</i>	08/24/1999	
<i>B</i>	AX	5,944,754		Vacanti	08/31/1999	
<i>B</i>	AY	6,027,744		Vacanti <i>et al.</i>	02/22/2000	

Examiner Signature	<i>[Signature]</i>	Date Considered	11/12/02
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act (60159-99), no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO				Complete if Known Application Number 09/585,821 Filing Date June 1, 2000 First Named Inventor Wilkison <i>et al.</i> Group Art Unit 1645 Attorney Docket Number 08140.ARTDIV	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				RECEIVED AUG 10 2001 TECHNICAL CENTER 1600/2900	
Sheet	2	of	4		

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clmns, Lns, Where Relevant Passages/Relevant Figs Appear
		Number (if known)	Kind Code			
<i>B</i>	BA	6,030,836		Thiede <i>et al.</i>	02/29/2000	
<i>B</i>	BB	6,103,522		Torok-Storb <i>et al.</i>	08/15/2000	
<i>B</i>	BC	6,123,727		Vacanti <i>et al.</i>	09/26/2000	
<i>B</i>	BD	6,139,574		Vacanti <i>et al.</i>	10/31/2000	
<i>B</i>	BE	6,143,501		Sittinger <i>et al.</i>	11/07/2000	
<i>B</i>	BF	6,153,432		Halvorsen <i>et al.</i>	11/28/2000	
<i>B</i>	BG	6,200,606		Peterson <i>et al.</i>	03/13/2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Date of Publication of Cited Document DD-MM-YYYY	Country	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
<i>B</i>	BH	WO	96/02662	A1	01/02/1996	PCT		
<i>B</i>	BI	WO	98/20731	A1	22/05/1998	PCT		
<i>B</i>	BJ	WO	99/28444	A1	10/06/1999	PCT		
<i>B</i>	BK	WO	99/61587	A1	02/12/1999	PCT		
<i>B</i>	BL	WO	99/43286	A2	02/09/1999	PCT		
<i>B</i>	BM	WO	00/44882	A2	03/08/2000	PCT		
<i>B</i>	BO	WO	00/53795	A1	14/09/2000	PCT		
<i>B</i>	BP	WO	01/21767	A2	29/03/2001	PCT		

Examiner Signature		Date Considered	11/12/02
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO				<div style="text-align: center;">  </div>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	09/585,821
				Filing Date	June 1, 2000
				First Named Inventor	Wilkison <i>et al.</i>
				Group Art Unit	1645
Attorney Docket Number	08140.ARTDIV				
Sheet	3	of	4		

RECEIVED
 AUG 10 2001
 TECH CENTER 1600 2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
6	CA	ARNER, "The β_3 -Adrenergic Receptor - A Cause and Cure of Obesity?" <u>New England Journal of Medicine</u> , (1995), 333:382-383	
8	CB	BARHAM <i>et al.</i> , "An Improved Colour Reagent for the Determination Blood Glucose by the Oxidase System," <u>Analyst</u> , (1972) 97:142-145	
6	CC	BECKER <i>et al.</i> , "Use of Recombinant Adenovirus for Metabolic Engineering of Mammalian Cells," <u>Meth Cell Biol.</u> (1994) 43:161-189	
6	CD	DIGBY <i>et al.</i> , "Thiazolidinedione Exposure Increases the Expression of Uncoupling Protein 1 in Cultured Human Preadipocytes," <u>Diabetes</u> , (1998), 47:138-141	
6	CE	DULBECCO <i>et al.</i> , "Plaque Production by the Polyoma Virus," <u>Virology</u> , (1959) 8:396	
8	CF	EARLE, "Production of Malignancy in Vitro. IV. The Mouse Fibroblast Cultures and Changes Seen in the Living Cells," <u>JNCI</u> , (1943), 4:165-169	
6	CG	FELGNER <i>et al.</i> , "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure," <u>Proc Natl Acad Sci USA</u> , (1987), 84:7413-7417	
8	CH	FLIER, "The Adipocyte: Storage Depot or Node on the Energy Information Superhighway?" <u>Cell</u> , (1995), 80:15-18	
6	CI	GREEN <i>et al.</i> , "Sublines of Mouse 3T3 Cells That Accumulate Lipid," <u>Cell</u> , (1974), 1:113-116	
8	CJ	HAM, "An Improved Nutrient solution for Diploid Chinese Hamster and Human Cell Lines," <u>Exp Cell Res.</u> , (1963) 29:515-526	
8	CK	HAUNER <i>et al.</i> , "Promoting Effect of Glucocorticoids on the Differentiation of Human Adipocyte Precursor Cells Cultured in a Chemically Defined Medium," <u>Journal Clin Invest.</u> , (1989) 34:1663-1670	
6	CL	HEYMAN <i>et al.</i> , "9-Cis Retinoic Acid Is a High Affinity Ligand for the Retinoid X Receptor," <u>Cell</u> , (1992), 68:397-406	
8	CM	HOTAMISLIGIL <i>et al.</i> , "Increased Adipose Tissue Expression of Tumor Necrosis Factor- α in Human Obesity and insulin Resistance," <u>J. Clin. Invest.</u> , (1995), 95:2409-2415	
6	CN	LEHMANN <i>et al.</i> , "An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPAR γ)*," <u>J. Biological Chemistry</u> , (1995), 270:12953-12956	

Examiner Signature		Date Considered	11/12/02
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO		<div style="text-align: center;">  </div>		<div style="text-align: right;"> Complete if Known </div>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/585,821		
		Filing Date	June 1, 2000		
		First Named Inventor	Wilkison <i>et al.</i>		
		Group Art Unit	1645		
Sheet 4 of 4	Attorney Docket Number		08140.ARTDIV		

AUG 10 2001
 TECH CENTER 1600 2900

RECEIVED

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
<i>§</i>	DA	MEUNIER-DURMONT <i>et al.</i> , "Efficient transfer of regulated genes in adipocytes and hepatoma cells by the combination of liposomes and replication-deficient adenovirus," <i>Eur Jour Biochem.</i> (1996), 237:660-667		
<i>§</i>	DB	MORTON, "A Survey of Commercially Available Tissue Culture Media," <i>In Vitro.</i> (1970) 6:89-108		
<i>§</i>	DC	NOLAN <i>et al.</i> , "Improvement in Glucose tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone," <i>New England Journal of Medicine.</i> (1994) 331:1188-1193		
<i>§</i>	DD	PELLEYMOUNTER <i>et al.</i> , "Effects of the obese Gene Product on Body Weight Regulation in ob/ob Mice," <i>Science.</i> (1995), 269:540-543		
<i>§</i>	DE	RODBELL <i>et al.</i> , "[7] Preparation of Isolated Fat Cells and Fat Cell "Ghosts": Methods for Assaying Adenylate Cyclase Activity and Levels of Cyclic AMP," <i>J. Biol. Chem.</i> , (1967) 242:104-114		
<i>§</i>	DF	RODBELL, "Metabolism of Isolated Fat Cells v. Preparation of "Ghosts" and their Properties; Adenyl Cyclase and Other Enzymes," <i>Journal of Biol Chem.</i> , (1967) 242:5744-5750		
<i>§</i>	DG	SALTIEL <i>et al.</i> , "Perspectives in Diabetes - Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes," <i>Diabetes.</i> (1996), 45:1661-1669		
<i>§</i>	DH	SMITH <i>et al.</i> , "The Nucleic acid of Polyoma Virus," <i>Virology.</i> (1960) 12:185-196		
<i>§</i>	DI	SREENAN <i>et al.</i> , "Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone," <i>American Journal Physiol.</i> (1996), 271:E742-E747		
<i>§</i>	DJ	TONTONOZ <i>et al.</i> , "Stimulation of Adipogenesis in Fibroblasts by PPAR γ 2, a Lipid-Activated Transcription Factor," <i>Cell.</i> (1994), 79:1147-1156		
<i>§</i>	DK	WIGLER <i>et al.</i> , "Transfer of Purified Herpes Virus Thymidine Kinase Gene to cultured Mouse Cells," <i>Cell.</i> (1977), 11:223-232		
<i>§</i>	DL	ZHANG <i>et al.</i> , "Positional cloning of the mouse <i>obese</i> gene and its human homologue," <i>Nature.</i> (1994) 372:425-432		

Examiner Signature		Date Considered	11/12/02
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.